Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

77 results about "Germline" patented technology

In biology and genetics, the germline in a multicellular organism is the population of its bodily cells that are so differentiated or segregated that in the usual processes of reproduction they may pass on their genetic material to the progeny.

Gossypium hirsutum wild germline salt-tolerant gene GhSHOU4 and application thereof

ActiveCN119120505AReduced toleranceElevated levels of malondialdehydePlant peptidesFermentationBiotechnologyNucleotide
The invention discloses an upland cotton wild germline salt-tolerant gene GhSHOU4 and application thereof, the gene ID of the cotton gene GhSHOU4 is GHA05G1741, and the nucleotide sequence of the cotton gene GhSHOU4 is as shown in the sequence 1. According to the invention, the wild germline gene GhSHOU4 of the upland cotton is cloned from the wild germline of the upland cotton, and a subcellular localization result shows that the GhSHOU4 protein is localized on a cytoplasmic membrane. Gene silencing cotton is obtained by using a VIGS technology, phenotype identification and physiological and biochemical index determination after salt stress treatment show that the malondialdehyde content of a gene silencing plant is significantly increased, and it is proved that the tolerance of the cotton after silencing the gene under salt stress is significantly reduced. Good gene resources are provided for salt-tolerant molecular breeding and genetic improvement of cotton.
Owner:SANYA NATIONAL INSTITUTE OF SOUTHERN BREEDING CHINESE ACADEMY OF AGRICULTURAL SCIENCES +1

End-to-end B cell clone pedigree forest construction method and related equipment

ActiveCN121438931AData visualisationBiostatisticsAlgorithmCognitive efficiency
The embodiment of the invention provides an end-to-end B cell clone pedigree forest construction method and related equipment, and can be applied to the technical field of data processing. According to the method, a plurality of obtained receptor sequencing sequences are subjected to germline comparison identification to obtain a first test Fv sequence corresponding to each receptor sequencing sequence, and a germline Fv sequence corresponding to each receptor sequencing sequence is generated; performing integrity filtering on the first test Fv sequence, performing clone type division to obtain a plurality of first clone type sets, constructing corresponding first evolutionary trees to form a first pedigree forest on the basis of a second clone type set contract type conversion probability, and performing node optimization on all the first evolutionary trees to obtain a second pedigree forest; and after it is determined that the homotype category conversion probability after updating based on all the second evolutionary trees meets the preset requirement, visualization processing is performed on all the second evolutionary trees, so that the systematic cognition efficiency of related personnel on the adaptive immune response mechanism can be improved.
Owner:广州赛业百沐生物科技有限公司

Methods for treatment of cancer

In one aspect, methods are provided for assessing or treating a subject diagnosed with a tumor, comprising 1) obtaining a biological sample from the subject; 2) identifying germline or somatic mutations in the subject's genome; 3) identifying copy number profiles across the genome; 4) analyzing T cell receptor (TCR) clonotypes; and 5) identifying subjects responsive to chemotherapy, immunotherapy or combined chemotherapy and immunotherapy. In certain aspects, the identified subjects may be administered a chemotherapeutic, an immunotherapeutic or a chemotherapeutic and an immunotherapeutic, and, thereby treating the subject.
Owner:JOHNS HOPKINS UNIVERSITY

Methods and systems for predicting the reliability of somatic / germline calls for variant sequences

Methods for determining the reliability of a prediction of somatic or germline origin for a variant sequence in a sample from a subject are described. The methods comprise determining a tumor fraction metric that characterizes a tumor fraction of the sample based on the sequence read data; determining a copy number metric for a variant sequence present in the sample based on the sequence read data; generating a reliability parameter for predicting somatic or germline origin for the variant sequence based on the tumor fraction metric and the copy number metric; and comparing the reliability parameter to a predetermined threshold to determine if the prediction of somatic or germline origin for the variant sequence is reliable.
Owner:FOUNDATION MEDICINE INC

Modified immunogenic proteins

The invention relates to germline-targeting designs, stabilization designs, and / or combinations thereof, of proteins designed with modified surfaces helpful for immunization regimens, other protein modifications and / or development of nanoparticles, methods of making and using the same, and to (a) germline-targeting priming or boosting / shepherding immunogens to initiate or guide maturation of VRC01-class responses (b) PCT64 / PG9-germline-targeting designs (c) BG18-germline-targeting designs or boosting / shepherding immunogens to initiate or guide maturation of BG18-like responses, and / or (d) trimer stabilization and presentation in a membrane-bound format.
Owner:INTERNATIONAL AIDS VACCINE INITIATIVE INC +1

Machine-learning model for recalibrating genotype calls corresponding to germline variants and somatic mosaic variants

PCT designated stage expiredWO2025006874A1BiostatisticsProteomicsGeneticsGenotype
This disclosure describes methods, non-transitory computer readable media, and systems that can utilize a machine-learning model to recalibrate genotype calls (e.g., variant calls) corresponding to germline variants and somatic mosaic variants. For instance, based on sequencing metrics for nucleotide reads of a genomic sample, the disclosed systems can utilize a variant-call-recalibration machine-learning model to generate genotype probabilities for variants within genomic regions corresponding to candidate germline variants and candidate somatic mosaic variants. Further, the disclosed systems can generate genotype calls, such as variant calls corresponding to somatic mosaic variants, based on the generated genotype probabilities.
Owner:ILLUMINA INC

Identification of somatic mutations versus germline variants for cell-free DNA variant calling applications

The present disclosure provides systems and methods to detect somatic or germline variants by providing a predetermined genomic DNA (gDNA) to an assay mixture, and capturing a sample of a subject's genetic information using a DNA sequencer and detecting genetic variants from the genetic information. A mutation may then be classified as being from a germline source if gDNA derived molecules have lengths inconsistent with those expected from cell-free DNA (cfDNA) derived molecules.
Owner:GUARDANT HEALTH INC

Systems and methods for characterizing mutations

PendingUS20260253673A1Germline mutationReference sample
Systems and methods for characterizing a mutation include obtaining reference sequence reads mapping to a genomic location of the mutation from a first sequencing reaction using a reference sample of a subject, and obtaining tumor sequence reads mapping to the genomic location of the mutation from a second sequencing reaction using a solid tumor sample of the subject. A reference base fraction of the mutation is determined using the reference sequence reads. A germline expectation of the mutation is determined using a tumor purity of the solid tumor sample, the major and the minor copy number at the genomic location of the mutation derived from tumor sequence reads. The reference base fraction and the germline expectation of the mutation are inputted into a model thereby obtaining, as output from the model, a determination of whether the mutation is a clonal hematopoiesis of indeterminate potential mutation or a germline mutation.
Owner:TEMPUS AI INC

Methods and systems for predicting allergic response

ActiveUS12467094B2Microbiological testing/measurementAllergic responseB cell
The present invention provides systems and methods for predicting an allergic response in a subject by measuring the amounts of RNA species from B cells that encode at least a part of the Immunoglobulin E (IgE) constant region (Cε), such as nonproductive epsilon germline transcripts (εGLTs).
Owner:IGGENIX INC

ADA response specificity assay

This article reports a method for determining the epitope of an antibody that specifically binds to a therapeutic antibody, the method comprising the steps of: a) culturing a sample comprising serum and the antibody that specifically binds to the therapeutic antibody separately with: i) at least one Fab fragment of the therapeutic antibody, and ii) at least one Fab fragment of the therapeutic antibody, wherein the HVRs that form the complementary site have been replaced by germline sequences, and detecting the binding or non-binding of the antibody that specifically binds to the therapeutic antibody to at least one Fab fragment in either i) or ii), and b) determining that the epitope of the antibody that specifically binds to the therapeutic antibody is in at least one HVR that has been replaced in ii), provided that binding is detected in i) and non-binding is detected in ii).
Owner:F HOFFMANN LA ROCHE & CO AG

A method and related device for analyzing and screening specificities of b cell immune repertoire antibody sequences

The application discloses a B cell immune repertoire antibody sequence feature analysis and specific screening method and related equipment, which can be applied to the technical field of data processing. According to the application, after the antibody sequencing sequence is subjected to germ line comparison and recognition to obtain corresponding first sequencing Fv sequence and germ line Fv sequence, the first sequencing Fv sequence is subjected to gene integrity filtering and structure integrity filtering, clonotype division and root node sequence reconstruction to obtain a second clonotype collection, and then a first lineage forest is constructed, and according to the second sequencing Fv sequence, the second clonotype collection or the first lineage forest, sequence feature analysis in multiple dimensions is carried out, so that the antibody sequence features can be analyzed from multiple dimensions such as sequence quality, sequence abundance, mutation degree, mutation preference and aggregation degree, the filtered BCR sequence has high affinity, and according to the sequence feature analysis results in multiple dimensions or the first lineage forest, a visualized graph is generated, so that relevant personnel can view the sequence features.
Owner:广州赛业百沐生物科技有限公司

Protein sequence prediction method, device and equipment based on large language model and storage medium

The invention provides a protein sequence prediction method and device based on a large language model, equipment and a storage medium, and the method comprises the steps: training an initial large language model based on a first sample data set, obtaining an intermediate large language model, generating a second sample data set according to original base sequence data, and obtaining a second sample data set; and training the intermediate large language model according to the second sample data set to obtain a target large language model, and inputting the to-be-predicted germline and the specified protein framework into the target large language model to obtain a protein sequence corresponding to the specified protein framework under the to-be-predicted germline. According to the method, the germline and the protein framework of the protein sequence are taken as prompt information, so that the finally obtained target large language model can generate the protein sequence by taking the germline and the protein framework as conditions, and the requirement of a user on generating the protein sequence by taking the germline as the condition is met.
Owner:SHENZHEN TECH UNIV

Low viscosity antigen-binding proteins and methods for producing them

PendingJP2026110678AHyperviscosityFc domain
This invention provides low-viscosity antigen-binding proteins and methods for producing them. [Solution] The present invention relates to a method for reducing the viscosity of an antigen-binding protein by modifying the sequence in the framework region and / or Fc domain, which has been shown to be associated with high viscosity. The present invention provides antigen-binding proteins, particularly antibodies, that have been mutated to reduce viscosity. Preferred antigen-binding proteins according to the present invention include antibodies, as shown in Figure 1B, having one or more, preferably all, of the following: VH1|1-18 germline subfamily substitution; VH3|3-33 germline subfamily substitution; VK3|L16 germline subfamily substitution; VK3|L6 germline subfamily substitution; or Fc substitution.
Owner:AMGEN INC

Genomic alteration of plant germline

Compositions containing chimeric RNA molecules which comprise meristem targeting sequences that are fused to RNA cargo sequences that include gene editing molecules are provided. Methods of using the compositions to efficiently edit plant genomes without intervening tissue culture steps are also provided. The solutions described here relate to engineered RNA molecules useful in producing plants with altered genomes. As such, it relates to substantially purified compositions, vectors, systems, as well as genomes of plants.
Owner:INARI AGRICULTURE TECHNOLOGY INC

Hybrid variant calling

PCT designated stageWO2026043987A1BiostatisticsProteomicsGeneticsVariome
A computer-implemented method for identifying a genomic variant is provided. The method includes obtaining one or more reference molecular sequences and sequencing data pertaining to a biological sample. One or more candidate variant positions are determined from the sequence reads for the biological sample. A classifier model is applied to each candidate variant position for selecting between a haplotype-aware or haplotype-agnostic variant analysis respectively. The classifier model is trained from haplotype structure and / or sequence reads identified with germline variants in a plurality of regions. Based on the application of the classifier model, respectively applying a haplotype-aware or haplotype-agnostic variant analysis to generate a variant identification for each candidate variant position.
Owner:ROCHE SEQUENCING SOLUTIONS INC

A method of generating sterile and monosex progeny

PCT designated stage expiredWO2024229156A3Animal cellsRecombinant DNA-technologyBroodstockCrustacean
The disclosure provides an endogenous germ cell-less fish, crustacean, or mollusk having a chimeric gonad, where the chimeric gonad comprises at least one transplanted germ cell having a mutation that is present in the germline and disrupts the development and / or function of somatic gonadal cells, which can be used as broodstock. The disclosure also provides methods of making broodstock fish, crustaceans, or mollusks for use in producing sterilized or sex-determined sterilized fish, crustaceans, or mollusks, as well as the broodstock itself.
Owner:CENT FOR AQUACULTURE TECH INC

Genetic complementary compositions and methods

In several exemplary embodiments herein, germline complementation methods and compositions, in particular NANOS3 deficient cells and non-human animals, are described. In some embodiments, the NANOS3 deficient non-human animal is germline ablated.
Owner:RGT UNIV OF CALIFORNIA

Methods for producing affinity-binding multispecific antibodies

Reported herein is a method for increasing the (avidity) binding specificity of a bispecific antibody comprising a first mammalian or mammalized binding site that specifically binds to a first (cell surface) antigen and a second binding site that specifically binds to a second (cell surface) antigen, wherein the first mammalian or mammalized binding site is at least a pair of an immunoglobulin light chain variable domain and an immunoglobulin heavy chain variable domain, by reducing the binding affinity of the mammalian or mammalized binding site to its antigen by mutating at least one amino acid residue in the first mammalian or mammalized binding site at a position located in a CDR of the light chain variable domain or in CDR1 or CDR2 of the heavy chain variable domain or in the two framework positions directly preceding CDR3 in the heavy chain variable domain to an amino acid residue that is present at said position in the germline immunoglobulin amino acid sequence of the same mammalian species as the species of the mammalian or mammalized binding site.
Owner:F HOFFMANN LA ROCHE & CO AG

An end-to-end method and related equipment for constructing B-cell clonal lineage forests

This application provides an end-to-end method and related equipment for constructing a B-cell clonal lineage forest, applicable to the field of data processing technology. This application identifies the first test Fv sequence corresponding to each receptor sequencing sequence by performing germline alignment on multiple acquired receptor sequencing sequences, and generates a germline Fv sequence corresponding to each receptor sequencing sequence. Then, the first test Fv sequences are filtered for integrity and further classified into several first clonal type sets. Based on these second clonal type sets and the same-type class conversion probability, corresponding first phylogenetic trees are constructed to form a first lineage forest. Node optimization is performed on all first phylogenetic trees. After confirming that the same-type class conversion probability meets preset requirements after updating all second phylogenetic trees, all second phylogenetic trees are visualized, thereby improving the efficiency of relevant personnel's systematic understanding of adaptive immune response mechanisms.
Owner:广州赛业百沐生物科技有限公司

Platform and method for determining critical transcription factors (TF) for TF-based human induced pluripotent stem cell (HIPSC) differentiation

A platform and method for determining critical transcription factors for TF-based hiPSC differentiation. The platform including: a transcriptomic dataset database; at least a processor; a memory communicatively connected to the processor, the memory containing instructions configuring the at least a processor to generate gene regulatory networks from transcriptomic datasets; determine a candidate transcription factor; analyze an impact of the candidate transcription factor in germline cell development; and output a set of critical transcription factors.
Owner:GAMETO INC

Methods and systems for differentiating somatic and germline variants

In an aspect, a method of identifying a somatic or germline origin of a nucleic acid variant from a sample of nucleic acid molecules comprises: determining quantitative measures for the nucleic acid variant comprising total allele count and minor allele count for the nucleic acid variant; identifying an associated variable of the nucleic acid variant; determining quantitative value for the associated variable; generating a statistical model for expected germline mutant allele counts at a genomic locus of the nucleic acid variant; generating a probability value (p-value) for the nucleic acid variant based at least in part on the statistical model, the quantitative value, and at least one of the quantitative measures; and classifying the nucleic acid variant as (i) being of somatic origin when the p-value is below a predetermined threshold value, or as (ii) being of germline origin when the p-value is at or above the predetermined threshold value.
Owner:GUARDANT HEALTH INC

Measurement method of sexual reproduction animal germline mutation rate and application

The invention provides a method for measuring the mutation rate of a sexual reproduction animal whole genome level nucleotide germline. The method comprises the following steps: (1) performing genome sequencing on a to-be-detected species to obtain sequences of all coding proteins of the to-be-detected species; (2) constructing a phylogenetic tree of a to-be-tested species; (3) obtaining the divergence time Tdivergence between the species to be detected and the sibling species; (4) optimizing the phylogenetic tree of the species to be tested; and (5) obtaining the annual germline mutation rate [mu] year of the species to be detected. The principle of the method is as follows: neutral regions or neutral sites are widely distributed in a genome, and mutations generated at the positions are generally not influenced by natural selection; the mutation rate of the germline can be calculated by analyzing the change of the variation frequency of the sites along with time. The method provided by the invention not only is widely applicable to sexual reproduction animal species with obtained genome or transcriptome data, but also is accurate and efficient, fills up the blank of the prior art, and has great significance in theoretical research and practical application of biomedical engineering.
Owner:OCEAN UNIV OF CHINA

Methods of improved somatic mutation detection

PCT designated stageWO2025221921A1ProteomicsGenomicsMutation detectionGenetics
Provided are germline mutational signatures that can improve somatic calling and detection of somatic mutational signatures.
Owner:MYRIAD GENETICS INC

Recombinant non-human animals for antibody production

The present invention provides genetically modified animals (e.g., mice), humanized heavy chain antibodies, humanized nanobodies, and methods for producing and using them. [Solution] Provided are genetically modified non-human animals (e.g., genetically modified mice) that can be designed to produce heavy chain antibodies that can be used to generate single-domain antibodies or nanobodies. In one embodiment, a genetically modified mouse is provided comprising a germline modification comprising deletion of nucleic acid sequences comprising one or more heavy chain C region genes; the genetically modified mouse expresses an IgG heavy chain antibody and secretes an IgG heavy chain antibody in its serum.
Owner:レヴェラージェンインコーポレーテッド

Context-Specific Tumor-Only Mutation Classification

Context-specific tumor-only mutation classification is described. A mutation classification module may classify a mutation identified in sequencing data from a tumor sample as germline or somatic based on a likelihood ratio relative to a threshold, the likelihood ratio comparing a germline model likelihood of a germline model of the mutation to a somatic model likelihood of a somatic model of the mutation and the threshold calculated based on a context of the mutation. The mutation classification module may output the classification of the mutation.
Owner:THE BROAD INST INC +1

Methods of assessing and monitoring tumor load

ActiveUS12716101B2Tumor LoadCell free
The invention disclosed herein generally relates to methods of assessing and monitoring tumor load through analysis of tumor DNA in cancer patients. Quantitative measures derived from cell-free DNA and germline DNA are used to assess and monitor tumor load. By assessing and monitoring tumor load, cancer may be detected in a subject. The tumor load of a subject may be assessed at a number of different time points to monitor a progression, regression, or recurrence of cancer in a subject.
Owner:LEXENT BIO INC